ABCG2/BCRP, expression of which is commonly associated with chemoresistance, was found to be significantly upregulated in tumor cells after neoadjuvant endocrine therapy in 3 separate cohorts of patients with primary breast cancer. Endocrine-induced upregulation of ABCG2/BCRP in vitro was associated with resistance to subsequent treatment with chemotherapy. Introduction: Neoadjuvant treatments for primary breast cancer are becoming more common; however, little is known about how these impact on response to subsequent adjuvant therapies. Conveniently, neoadjuvant therapy provides opportunities to consider this question, by studying therapy-induced expression changes using comparisons between pre-and posttreatment samples. These data are relatively lacking in the context of neoadjuvant endocrine therapy, as opposed to the more common neoadjuvant chemotherapy. Here, we investigate the relevance of expression of the xenobiotic transporter ABCG2/BCRP, a gene/protein associated with chemoresistance, in the context of neoadjuvant endocrine therapy and particularly with reference to subsequent chemotherapy treatment. Materials and Methods: ABCG2/BCRP expression was assessed by immunohistochemistry or by expression arrays in matched patient samples pre-and post-neoadjuvant endocrine therapy. Cell culture was used to model the impact of endocrine therapy-induced changes in ABCG2/BCRP on subsequent chemotherapy response, using Western blots, quantitative polymerase chain reaction, survival assays, and cell cycle analyses. Results: ABCG2/BCRP was commonly and significantly upregulated in breast cancers after treatment with neoadjuvant endocrine therapy in 3 separate cohorts encompassing a total of 200 patients. Treatment with the endocrine therapeutic tamoxifen similarly induced ABCG2/ BCRP upregulation in a relevant model cell line, the estrogen receptor-positive line T47D. Critically, this upregulation was associated with significantly increased chemoresistance to subsequent treatment with epirubicin, an anthracycline commonly used in breast cancer adjuvant chemotherapy. Conclusion: Our data suggest that neoadjuvant endocrine therapy may induce poor responses to adjuvant chemotherapy, and therefore, that clinical outcomes following this treatment sequence warrant further study.
Introduction
Use of neoadjuvant therapies for treatment of primary breast cancer is becoming more frequent for at least 2 reasons. First, these therapies can downstage tumors, thereby enabling increased rates of breast conserving surgery as opposed to mastectomy. 1 Second, they can provide opportunities to assess tumor responses to specific therapeutics using longitudinal imaging and clinical assessments, therefore allowing switching to potentially more effective treatment regimens if initial responses are deemed inadequate. 2 Chemotherapy is the most common neoadjuvant approach; however, neoadjuvant endocrine therapy (NAET) is preferred in some patients with estrogen receptor-positive (ER þ ) disease, 3 and is particularly accepted in patients who are elderly, frail, or have problematic comorbidities; and therefore, extended nonsurgical management may be desirable. 4 Increased consideration of NAET in selected patients has recently been recommended 5, 6 on account of similar overall response rates to neoadjuvant chemotherapy 3 with lower toxicity, 7 although it should be noted that complete pathologic responses are far rarer with NAET. It has also been suggested that clinical or molecular responses to NAET should be integrated with other factors to stratify patients to appropriate adjuvant treatments such as chemotherapy. 8, 9 Use of neoadjuvant therapies provides powerful opportunities to assess molecular responses of cancers to specific therapies by comparison between matched pretreatment diagnostic samples and posttreatment resection samples. These comparisons are quite prevalent in the context of neoadjuvant chemotherapy, both at the level of individual genes or at the transcriptome level, [10] [11] [12] but many fewer studies are available for NAET, with only a handful of transcriptome-wide investigations. [13] [14] [15] [16] [17] A focus of many of these studies has been identification of potential induced mechanisms of resistance to the given neoadjuvant therapy. Little attention has been given to how molecular changes resulting from these neoadjuvant therapies might impact on response to subsequent adjuvant treatments. This question may have growing importance if response to NAET is to be used to stratify patients for assignment to adjuvant chemotherapy. 8, 9 We have an interest in roles of xenobiotic drug pumps in resistance to cancer therapies, and have previously shown that expression of breast cancer resistance protein (BCRP), encoded by the ABCG2 gene, can be associated with poor survival after chemotherapy in breast cancer. 18 In this new work, we were interested to assess whether NAET impacted on expression of ABCG2/BCRP, and whether this could have implications for subsequent adjuvant chemotherapy responses.
Material and Methods

Patient Selection, Ethical Approval, and Immunohistochemistry
Ethical approval for use of patient samples and anonymized data and for the consent process used was obtained from Leeds (East) Research Ethics Committee (reference 06/Q1206/180). Informed consent was obtained when appropriate. Patients with primary breast cancer who were treated with neoadjuvant endocrine therapy (NAET) at Leeds Teaching Hospitals NHS Trust from 2005 to 2013 were identified. Criteria for inclusion in our study were NAET duration of 1 month to 1 year, NAET alone without combination therapy (for example, excluding individuals on the NEO-EXCEL trial who additionally received celecoxib), a diagnosis of invasive ductal or lobular carcinoma, Allred score for estrogen receptor expression of 7 or 8, no change in NAET regime during treatment, and lack of human epidermal growth factor receptor 2 overexpression. In addition, we required that tissue before NAET (diagnostic biopsies) and after NAET (resection) was available. This identified a cohort of 51 patients. Relevant clinicopathologic data are outlined in Table 1 . Tissues were sectioned at 5 mm onto SuperFrost Plus slides (Menzel-Glaser, Braunschweig, Germany). Matched biopsy and resection samples were placed on the same single slide; therefore, subsequent staining/analysis conditions for the pairs were identical and relative expression between them was directly comparable. Immunohistochemistry was performed and quantified exactly as described previously. 18 In brief, sections were dewaxed and rehydrated, and further antigen retrieval was not necessary. BCRP staining was visualized using Envision reagents (Dako, Gostrup, Denmark) and sections were counterstained in Mayer's hematoxylin. Sections were digitally scanned using Scanscope XT and were analyzed using Imagescope (Aperio, Vista). Staining was assessed under guidance of breast histopathologists (A.M.H. and E.T.V.). Positive (brown) staining was quantified in tumor cells only by weighted histoscores using a semi-automated protocol, validated extensively previously. 18 In brief, tumor epithelial regions were manually marked on digital images, and positive staining was quantified within these using the positive pixel count algorithm in 3 NAET Upregulates BCRP, With Implications for Subsequent Chemotherapy intensity ranges to ape manual scoring (counts of < 100 defined as weakly positive, 100 to < 175 as moderate, and 175 as strong). Percentages of total pixels categorized into each intensity band were used to determine automated histoscores: (1 Â % weakly positive pixels) þ (2 Â % moderate) þ (3 Â % strong).
Cell Culture and Drug Treatments
T47D cells were obtained originally from the European Collection of Animal Cell Cultures. Cell line identity was confirmed (STR profiles, Leeds Genomics Service), and cells were consistently negative for mycoplasma (MycoAlert Mycoplasma detection assay, Lonza, Basel, Switzerland). Cells were cultured in DMEM supplemented with 10% fetal calf serum and 1% penicillin/streptomycin (reagents from Thermo Fisher, Waltham, MA). Cells were treated with final concentrations of 1 mM or 5 mM tamoxifen (Sigma, Poole, UK) or appropriate amounts of ethanol (the vehicle for tamoxifen), namely 0.1% (v/v) or 0.5% (v/v) ethanol and incubated as normal.
Harvesting Protein and RNA
Cells were harvested using trypsin and divided, with threequarters of the cells to be used for protein extraction and the remainder used for RNA extraction. Cells were washed with phosphate buffered saline (PBS). For protein extraction, cells were washed again with PBS before being lysed for 15 minutes on ice in RIPA buffer (10mM Tris-HCl, 140mM NaCl, 0.1% SDS, 1% Triton X-100, 0.1% sodium deoxycholate) supplemented with the chelating agents EDTA and EGTA and the protease inhibitor PMSF (Sigma). RNA extraction was performed using Promega's (Madison, WI) RNA extraction kit using the manufacturer's instructions. In brief, cells were lysed in BL buffer supplemented with thio-glycerol. Isopropanol was added and the sample added to a spin column. Samples were washed and treated with DNase I before being eluted in nuclease-free water.
Expression Analyses (Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis [SDS-PAGE] and Western Blotting; Quantitative Polymerase Chain Reaction [qPCR])
SDS-PAGE and transfers were performed as described previously 20 using 4% to 12% Bis-Tris gels, PVDF membrane, and other reagents from Thermo Fisher (Waltham, MA). After transfer, membranes were blocked in 1 or 5% milk in TBS-T. Antibodies were diluted in 1% milk/ TBS-T. Primary antibodies (anti-beta-actin, 1:10000, Sigma) or anti-BCRP (clone BXP-21, 1:250, Abcam, Cambridge, UK) were incubated overnight at 4 C followed by washing with TBS-T then incubation with the secondary antibody (anti-mouse HRP conjugate, 1:2000, Abcam) for 1 hour. Blots were visualized using SuperSignal West Pico (Thermo Fisher) and Bio-Rad Gel Doc Imaging system, and quantified using Image Lab software (version 5.2.1). Reverse transcription of RNA was performed using the GoScript Reverse Transcription System (Promega) according to the manufacturer's instructions. In brief, total RNA was diluted in nuclease-free water before incubation with random primers at 70 C for 5 minutes. A reaction buffer mixture including reverse transcriptase and nucleotides was then added, and the reactions were placed in a controlled temperature heat block at 42 C to allow reverse transcription to occur. Quantification of mRNA levels of the control (beta-actin) and the gene of interest (ABCG2) was performed using the GoTaq qPCR Master Mix kit (Promega) according to the manufacturer's instructions. In brief, a total volume of 10 ml was plated in a 96-well plate containing diluted cDNA, CXR Reference Dye, GoTaq qPCR Master Mix, and forward and reverse primers for each gene of interest (actin: 5'-TTCTA-CAATGAGCTGCGTGTG-3' and 5'-GGGGTGTTGAAGGTCT-CAAA-3'; ABCG2: 5'-CAGGTGGAGGCAAATCTTCGT-3' and 5'-ACACACCACGGATAAACTGA-3'). Reactions were performed in the ABI 7500 qPCR machine (Thermo Fisher).
Cell Viability Assay (MTT)
After 15 days of treatment with tamoxifen, fresh media was placed on the cells for 24 hours. Cells were then trypsinized and plated into 96-well plates (Corning, NY). Cells were left for another 24 hours before being treated with 2.6 mM or 10 mM epirubicin (Sigma) or water (the vehicle for epirubicin), and incubated as normal for a further 24 hours. MTT assays (Thermo Fisher) were then performed as previously described, 21 with readings taken using the Mithras LB 940 Multimode Microplate Reader (Berthold Technologies, Harpenden, UK).
Cell Cycle Analysis
After pretreatment with tamoxifen, cells were given fresh media for 24 hours. Cells were then fixed in 70% ethanol for 2 hours. Cells were washed then resuspended in PBS before addition of propidium iodide (Sigma) at 0.02 mg/mL and RNase A (Thermo Fisher) at 0.4 mg/mL. After incubation for 20 minutes at room temperature in the dark, cell cycle status was analyzed using the Attune Acoustic Focusing Cytometer (Thermo Fisher) and accompanying Attune Cytometric Software Version 2.1.
Analysis of Publicly Available Gene Expression Datasets
Microarray data from related breast cancer studies looking at primary tumors or cell lines were downloaded from NCBI Gene Expression Omnibus (www.ncbi.nlm.nih.gov/geo/). Primary tumor datasets looking at the effects of 2 weeks and 3 months of letrozole from Edinburgh (GSE20181) and 2 weeks of an unspecified aromatase inhibitor in Houston (GSE87411) were considered, along with a dataset of breast tumors that were untreated between diagnosis and surgery, again from Edinburgh (GSE76728). Gene expression data on MCF7 breast cancer cell line following tamoxifen treatment (GSE21618) and long-term estrogen deprivation (GSE20361) were also considered. Normalized preprocessed data was used in all cases.
Results
ABCG2/BCRP is Upregulated Post-NAET in Patients With Breast Cancer
We were interested to study changes in expression patterns in primary breast tumors induced by NAET. Because we have previously studied xenobiotic drug pumps that are known to impact on outcomes in breast cancer, 18, 20 we focused on one of these pumps e ABCG2/BCRP. We identified a cohort of 51 patients with breast cancer treated with NAET in Leeds and for whom tumor tissue was available from both pre-NAET (diagnostic biopsies) and post-NAET (resection tissue). Clinicopathologic
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Clinical Breast Cancer December 2018 -483 details of these patients are shown in Table 1 . We detected BCRP using immunohistochemistry, and quantified expression objectively using an automated scoring system, as previously described. 18 Representative staining in a matched pair of pre-and post-NAET samples is shown in Figure 1A , whereas expression levels in all samples are shown in Figure 1B , with lines indicating the matched samples from individual patients for comparison. Expression was upregulated after NAET in 48 (94%) of 51 cases, and upregulation was significant overall (P < .0001) ( Figure 1B ). To confirm whether ABCG2 was increased in other breast cancer cohorts following endocrine treatment, we examined published microarray mRNA expression datasets of matched samples from patients with breast cancer, taken before and after aromatase inhibitor treatment. Levels of ABCG2 was found to be upregulated after NAET in the majority of patients in 2 cohorts from Edinburgh and Houston 14,15 after 2 weeks and 3 months, and upregulation was significant (P < .01 in all cases; paired Wilcoxon).
By way of a negative control, ABCG2 expression was not significantly changed (P ¼ .12) in a cohort of 37 breast tumors that did not receive treatment between diagnosis and surgery, 22 ( Figure 1C) where the interval ranged from 13 to 53 days (mean, 27.5 days). 
Breast Cancer Cell Lines
Having determined that ABCG2/BCRP is upregulated post-NAET in patients, we were interested to investigate whether this could be reproduced in vitro using a breast cancer cell line, and if so, what the implication of this might be. Therefore, we treated the ER þ cell line T47D with the endocrine therapeutic tamoxifen and examined BCRP/ABCG2 expression using Western blots and/or qPCR. BCRP was upregulated as quickly as 7 hours after treatment with 1 mM tamoxifen (Figure 2A ), and this upregulation increased with up to 3 days of continuous treatment ( Figure 2B ). Significant and dose-dependent upregulation of both transcript (ABCG2) and protein (BCRP) was evident after 15 days of continuous tamoxifen treatment at 1 and 5 mM ( Figure 2C ). Using publically available datasets, 23, 24 we have also shown upregulation of ABCG2 in response to 1 mM tamoxifen treatment and in response to estrogen (E2) withdrawal in another ER þ cell line, MCF7
( Figure 2D ), suggesting that our findings are not limited to T47D cells. Physiological intratumoral concentrations of tamoxifen have been estimated as between 0.5 and 2 mM [25] [26] [27] ; therefore, these doses used in vitro are within an appropriate range.
Tamoxifen Pretreatment Leads to Resistance to Subsequent Chemotherapy in Vitro
Increased ABCG2/BCRP expression can be associated with resistance to many standard cytotoxic chemotherapeutics, 28 ,29 so we were next interested to assess whether tamoxifen-induced changes in ABCG2/BCRP expression would have an impact on subsequent chemoresponse. Therefore, we again treated cells with control or 2 different doses of tamoxifen (1 or 5 mM) for 15 days, before removing tamoxifen and treating with control or 2 different doses of epirubicin (2.6 or 10 mM), an anthracycline chemotherapeutic drug frequently used in breast cancer treatment and known to be an AGCG2 substrate. 30 Relative cell survival was determined using MTT assays ( Figure 3A) . In cells without tamoxifen pretreatment (black bars), epirubicin treatment caused a dose-dependent reduction in cell survival of up to 76%. Pretreatment with either dose of tamoxifen increased cell survival from epirubicin, most notably the higher tamoxifen dose giving significant protection from 10 mM epirubicin (P < .05) with increased survival by more than 2-fold. One explanation for the chemoresistance shown by cells pretreated with tamoxifen would be that tamoxifen-induced exit from cell cycle was providing protection from the effects of epirubicin, which at least in part targets cells undergoing DNA replication. In order to support or refute this hypothesis, we next examined the influence of 15 days of tamoxifen treatment on the cell cycle in T47D cells using propidium iodide staining and flowcytometry ( Figure 3B ). There were no significant alterations in the cell cycle profile of tamoxifen pretreated cells, providing no support for the hypothesis that cell cycle changes were responsible for the increased chemoresistance. In this context, we believe our data support a direct functional role for BCRP upregulation in chemoresistance after endocrine treatment.
Discussion
Here, we present the first study to address the influence of NAET on ABCG2/BCRP expression in clinical cohorts of breast cancers. A number of previous studies have assessed the impact of estrogens on Figure 1 ). The upregulation of BCRP we observe after tamoxifen treatment in T47D cells (Figure 2 ) is compatible with all studies in this cell line that have looked at endogenous protein, and similar increases in ABCG2 were observed for tamoxifen treatment or E2 withdrawal in MCF7 cells.
Conclusion
A concerning conclusion from these observations is that NAETinduced upregulation of ABCG2/BCRP could potentially reduce the efficacy of adjuvant chemotherapy treatment in patients with breast cancer. We have attempted to model this effect using T47D cells, in which ABCG2/BCRP is upregulated after initial treatment with tamoxifen. We find clear evidence that pretreatment with tamoxifen protects the cells from chemotherapy, and this appears to be independent of any cell cycle effects (Figure 3) . Unfortunately, the hypothesis that patients who received NAET respond relatively poorly to adjuvant chemotherapy is not easy to test using existing clinical data because treatment with NAET followed by adjuvant chemotherapy is currently an uncommon clinical pathway. From our initial Leeds cohort of 51 patients in which we examined BCRP expression pre-and post-NAET, only 6 patients received adjuvant chemotherapy. From the Edinburgh cohort of 55, only 2 received adjuvant chemotherapy. Therefore, outcome data on a large enough number of patients are not available to evaluate the effect of NAET on adjuvant chemotherapy. Furthermore, it is not clear what represents a suitable comparator group to allow relative assessment of chemotherapy response, because patients who receive NAET are typically deemed suitable for this therapy for specific clinical reasons that likely mean they areh not usefully comparable wit other groups. A formal randomized clinical trial may be the only way to allow a robust assessment of whether NAET negatively influences responses to adjuvant chemotherapy; such a trial is unlikely and even if it took place, outcomes would not be known for many years as these ER þ cancers overall have good prognoses and recurrences tend to be late. However, the potential for NAET to impair responses to chemotherapy may well be worth noting for the future, particularly in the context that it has been suggested that response to NAET could be a useful tool to stratify patients to adjuvant chemotherapy, 8, 9 and some have combined endocrine therapy with chemotherapy in the neoadjuvant context. 35 Our results suggest that analyses of outcomes with these approaches in the future is warranted.
Clinical Practice Points
NAET is an appropriate breast cancer treatment in certain patient groups. It is not known how NAET impacts on response to subsequent adjuvant treatments. NAET was found to induce expression of a mediator of chemoresistance in patient cohorts, and to induce chemoresistance in a cell-line model. Clinicians should consider whether use of NAET could reduce the efficacy of subsequent chemotherapy.
